4/10
10:23 am
amgn
Amgen (AMGN) had its price target raised by Morgan Stanley from $309.00 to $326.00. They now have an "equal weight" rating on the stock.
Low
Report
Amgen (AMGN) had its price target raised by Morgan Stanley from $309.00 to $326.00. They now have an "equal weight" rating on the stock.
4/9
09:45 am
amgn
Amgen (AMGN) had its price target raised by Guggenheim from $347.00 to $351.00. They now have a "neutral" rating on the stock.
Low
Report
Amgen (AMGN) had its price target raised by Guggenheim from $347.00 to $351.00. They now have a "neutral" rating on the stock.
4/8
09:09 am
amgn
Amgen (AMGN) had its "neutral" rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
Low
Report
Amgen (AMGN) had its "neutral" rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
4/7
09:42 am
amgn
Amgen (AMGN) had its price target raised by Royal Bank Of Canada from $360.00 to $370.00. They now have an "outperform" rating on the stock.
Low
Report
Amgen (AMGN) had its price target raised by Royal Bank Of Canada from $360.00 to $370.00. They now have an "outperform" rating on the stock.
4/6
09:21 am
amgn
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE [Yahoo! Finance]
Low
Report
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE [Yahoo! Finance]
4/6
09:12 am
amgn
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE [TheStreet.com]
Low
Report
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE [TheStreet.com]
4/6
09:00 am
amgn
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Low
Report
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
4/2
11:49 am
amgn
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? [Yahoo! Finance]
Low
Report
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? [Yahoo! Finance]
4/1
10:43 am
amgn
Zai Lab gains after clinical trial pact with Amgen [Seeking Alpha]
Low
Report
Zai Lab gains after clinical trial pact with Amgen [Seeking Alpha]
3/30
04:48 pm
amgn
Bristol Myers Squibb adding 3 medications on TrumpRx [FOX Business Network]
Low
Report
Bristol Myers Squibb adding 3 medications on TrumpRx [FOX Business Network]
3/30
11:02 am
amgn
Teva gains approval of biosimilar of Amgen's Prolia [Seeking Alpha]
Low
Report
Teva gains approval of biosimilar of Amgen's Prolia [Seeking Alpha]
3/30
07:15 am
amgn
Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen” [Yahoo! Finance]
Low
Report
Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen” [Yahoo! Finance]
3/28
05:19 pm
amgn
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS [Yahoo! Finance]
Low
Report
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS [Yahoo! Finance]
3/28
04:45 pm
amgn
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Low
Report
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
3/26
10:46 am
amgn
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts [Yahoo! Finance]
Neutral
Report
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts [Yahoo! Finance]
3/19
09:16 am
amgn
Amgen (AMGN) had its price target raised by Wells Fargo & Company from $375.00 to $390.00. They now have an "equal weight" rating on the stock.
Low
Report
Amgen (AMGN) had its price target raised by Wells Fargo & Company from $375.00 to $390.00. They now have an "equal weight" rating on the stock.
3/17
04:48 pm
amgn
Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position [Yahoo! Finance]
Low
Report
Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position [Yahoo! Finance]
3/15
02:52 pm
amgn
Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies [Yahoo! Finance]
Low
Report
Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies [Yahoo! Finance]
3/15
10:29 am
amgn
Amgen's TrumpRx Discounts and Dividend Hike Might Change The Case For Investing In Amgen (AMGN) [Yahoo! Finance]
Low
Report
Amgen's TrumpRx Discounts and Dividend Hike Might Change The Case For Investing In Amgen (AMGN) [Yahoo! Finance]
3/14
09:52 am
amgn
Amgen and GSK said to be adding products on TrumpRx [Seeking Alpha]
Low
Report
Amgen and GSK said to be adding products on TrumpRx [Seeking Alpha]
3/13
09:59 pm
amgn
4 Biotech Stocks to Watch for Potential Upside in 2026 [Yahoo! Finance]
Low
Report
4 Biotech Stocks to Watch for Potential Upside in 2026 [Yahoo! Finance]
3/13
07:36 pm
amgn
Two major drug companies are the latest to join TrumpRx [FOX Business Network]
Low
Report
Two major drug companies are the latest to join TrumpRx [FOX Business Network]
3/12
10:56 am
amgn
Rapid Micro Biosystems Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Rapid Micro Biosystems Q4 Earnings Call Highlights [Yahoo! Finance]
3/11
10:11 pm
amgn
Amgen Touts 2025 Double-Digit Growth, MariTide Obesity Push and BiTE Momentum at Leerink Conference [Yahoo! Finance]
Low
Report
Amgen Touts 2025 Double-Digit Growth, MariTide Obesity Push and BiTE Momentum at Leerink Conference [Yahoo! Finance]
3/11
11:57 am
amgn
Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]